搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

  1. 首頁(yè)
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Kallistatin(SERPINA4) ELISA kit

Human Kallistatin(SERPINA4) ELISA kit

  • 中文名稱：
    人激肽釋放酶結(jié)合蛋白(SERPINA4)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-EL021060HU
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人激肽釋放酶結(jié)合蛋白(SERPINA4)酶聯(lián)免疫試劑盒（CSB-EL021060HU）為雙抗夾心法ELISA試劑盒，定量檢測(cè)血清、血漿、組織勻漿樣本中的SERPINA4含量。SERPINA4，也稱為Kallistatin，是一種主要在肝細(xì)胞中表達(dá)的分泌蛋白。它通過調(diào)節(jié)脂質(zhì)代謝和炎癥反應(yīng)，在非酒精性脂肪肝?。∟AFLD）和阿爾茨海默?。ˋD）的發(fā)生發(fā)展中發(fā)揮關(guān)鍵作用。研究顯示，SERPINA4通過影響關(guān)鍵信號(hào)通路和酶的活性，參與調(diào)控肝臟脂肪變性和炎癥反應(yīng)，以及認(rèn)知功能的下降。試劑盒檢測(cè)范圍為0.156 ng/mL-10 ng/mL，靈敏度為0.039 ng/mL。適用于基礎(chǔ)科研中探究SERPINA4在高血壓、動(dòng)脈粥樣硬化等疾病模型中的表達(dá)變化，或用于評(píng)估炎癥反應(yīng)、組織修復(fù)等生物過程中激肽釋放酶系統(tǒng)的調(diào)控機(jī)制，為心血管、代謝性疾病等領(lǐng)域的分子機(jī)制研究提供可靠工具。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名：
    KAIN_HUMAN ELISA Kit; KAL ELISA Kit; Kallikrein binding protein ELISA Kit; Kallikrein inhibitor ELISA Kit; Kallistatin ELISA Kit; KBP ELISA Kit; KLST ELISA Kit; KST ELISA Kit; MGC108582 ELISA Kit; Peptidase inhibitor 4 ELISA Kit; PI-4 ELISA Kit; PI4 ELISA Kit; Protease inhibitor 4 (kallistatin) ELISA Kit; Protease inhibitor 4 ELISA Kit; Serine (or cysteine) proteinase inhibitor; clade A (alpha 1 antiproteinase; antitrypsin); member 4 ELISA Kit; Serpin A4 ELISA Kit; Serpin peptidase inhibitor clade A member 4 ELISA Kit; Serpin peptidase inhibitor; clade A (alpha 1 antiproteinase; antitrypsin); member 4 ELISA Kit; SERPINA4 ELISA Kit; Tissue kallistatin inhibitor ELISA Kit
  • 縮寫：
    SERPINA4
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測(cè)范圍：
    0.156 ng/mL-10 ng/mL
  • 靈敏度：
    0.039 ng/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Others
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%        
    Three samples of known concentration were tested twenty times on one plate to assess.    
    Inter-assay Precision (Precision between assays): CV%<10%        
    Three samples of known concentration were tested in twenty assays to assess.      
                   
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human SERPINA4 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
    　 Sample Serum(n=4)    
    1:5000 Average % 92    
    Range % 87-98    
    1:10000 Average % 103    
    Range % 98-108    
    1:20000 Average % 92    
    Range % 90-98    
    1:40000 Average % 94    
    Range % 92-96    
  • 回收率：
    The recovery of human SERPINA4 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
     
    Sample Type Average % Recovery Range    
    Serum (n=5) 99 93-104    
    EDTA plasma (n=4) 94 89-97    
                   
                   
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
     
    ng/ml OD1 OD2 Average Corrected    
    10 2.432 2.565 2.499 2.337    
    5 2.056 2.066 2.061 1.899    
    2.5 1.442 1.457 1.450 1.288    
    1.25 0.889 0.956 0.923 0.761    
    0.625 0.535 0.544 0.540 0.378    
    0.312 0.355 0.375 0.365 0.203    
    0.156 0.268 0.274 0.271 0.109    
    0 0.168 0.155 0.162 　    
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 最新研究進(jìn)展：
    SERPINA4，又稱為Kallistatin，是一種抗凝血和抗炎蛋白質(zhì)。最新研究表明，Kallistatin可能對(duì)肺部疾病、心血管疾病、炎癥等具有保護(hù)作用。
  • 功能：
    Inhibits human amidolytic and kininogenase activities of tissue kallikrein. Inhibition is achieved by formation of an equimolar, heat- and SDS-stable complex between the inhibitor and the enzyme, and generation of a small C-terminal fragment of the inhibitor due to cleavage at the reactive site by tissue kallikrein.
  • 基因功能參考文獻(xiàn)：
    1. Kallistatin levels may provide useful information regarding cardiovascular risk in women with polycystic ovary syndrome PMID: 28294594
    2. Kallistatin functions as an endogenous lymphangiogenesis inhibitor and has an important part in the lymphatic metastasis of gastric cancer.Kallistatin was reduced in the cancer tissue and plasma of gastric cancer patients. PMID: 29243194
    3. SNPs rs2093266 in the SERPINA4 is associated with the development of severe acute kidney injury (KDIGO stage 2-3) in critically ill patients with septic shock PMID: 28270177
    4. oxidative stress induces down- or upregulation of kallistatin expression, depending on oxygen concentration, and kallistatin plays a novel role in mediating oxygen/exercise-induced HIF-1-eNOS-NO pathway. PMID: 29387292
    5. These findings reveal novel mechanisms of kallistatin in protection against senescence, aging, and cancer development by modulating miR-34a and miR-21 levels and inhibiting oxidative stress. PMID: 28744338
    6. These findings suggested that kallistatin may be a promising agent that could be used to suppress cancer metastasis by inhibiting both angiogenesis and lymphangiogenesis. PMID: 28440474
    7. generated a meta-marker model made up of SERPINA4 and PON1 that is useful as a differential diagnostic biomarker differentiating lung cancer from other lung diseases. PMID: 27168012
    8. The kallistatin's dual roles in angiogenesis, apoptosis and oxidative stress contribute to its beneficial effects in various diseases. PMID: 28742513
    9. Our results indicate that during severe sepsis and septic shock, a decrease in plasma concentrations of kallistatin reflects increased severity and poorer outcome of disease. PMID: 28542440
    10. data suggest that overexpression of kallistatin interferes with lymphopoiesis, ultimately impacting the level of circulating CD19(+) B lymphocytes. PMID: 28299632
    11. Kallistatin levels were correlated with some markers of systemic inflammation in the HIV population. PMID: 27326658
    12. Increased kallistatin levels in type 1 diabetes and its relation with carotid intima media thickness may reflect vascular dysfunction and suggest a link between micro- and macro-angiopathy. PMID: 26091968
    13. reveal novel mechanisms of kallistatin in inducing apoptosis and autophagy in breast cancer cells PMID: 26790955
    14. crystal structure of kallistatin 1.9 A resolution PMID: 26323298
    15. Kallistatin protects against renal ischemia-reperfusion injury by blocking oxidative stress and renal inflammation. PMID: 25654330
    16. Plasma kallistatin is a novel marker for severe community-acquired pneumonia prognosis. PMID: 23394256
    17. decreased SPTBN1 and kallistatin gene expression associated with decreased relapse-free survival in hepatocellular carcinoma PMID: 25307947
    18. these findings added the knowledge for us to understand the anti-angiogenic mechanism of kallistatin, which suggested that the rhKal could be worth as a candidate compound for further development for the purpose of anti-angiogenic therapies PMID: 24129914
    19. A novel role of kallistatin in preventing breast tumor growth and mobility by direct interaction with LRP6. PMID: 23666756
    20. As a potent antioxidant and anti-inflammation agent, kallistatin may also hold therapeutic promise in cardiometabolic disorders. PMID: 23190873
    21. Genotyping reveals two single nucleotide polymorphisms in the BCL2 gene and a single nucleotide polymorphism in the SERPINA4 gene associated with a decreased risk of developing acute kidney injury. PMID: 22710204
    22. Systemic administration of lentiviral vectors encoding kallistatin inhibited the growth of metastatic lung tumors and prolonged the survival of tumor-bearing mice. PMID: 20509975
    23. Delivery of human kallistatin cDNA to ischemic rat hindlimb and breast tumor xenografts showed that Kallistatin is a new inhibitor of angiogenesis and tumor growth. PMID: 12384424
    24. Results indicate that the heparin-binding domain, but not the reactive site loop of kallistatin, is essential for inhibiting vascular endothelial growth factor-induced angiogenesis. PMID: 12734113
    25. KBP reduces expression of VEGF and HIF-1alpha nuclear translocation PMID: 17714861
    26. Adeno-associated virus-mediated expression of KAL inhibits the growth of colon cancer by reducing angiogenesis and proliferation of tumor cells. PMID: 17729417

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Secreted.
  • 蛋白家族：
    Serpin family
  • 組織特異性：
    Expressed by the liver and secreted in plasma.
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 8948

    OMIM: 147935

    KEGG: hsa:5267

    STRING: 9606.ENSP00000298841

    UniGene: Hs.719893